Silence Therapeutics plc

Earnings Release • Jun 27, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8114K

Silence Therapeutics PLC

27 June 2014

27 June 2014

Silence Therapeutics plc

Result of General Meeting

Silence Therapeutics plc, AIM: SLN ('Silence'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

Silence Therapeutics plc	+44 (0)20 3700 9711
Timothy Freeborn, Finance Director & Company Secretary
Rozi Morris, Communications Manager
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor

About Silence Therapeutics plc    (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNAi (RNA interference) therapeutics platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.

Listed on London's AIM since 2006, Silence is one of only six quoted companies globally with well-validated RNA delivery technology.  It has a robust IP estate, with three Phase II trials already completed (pending results). 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSEIFIWFLSEFM